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Aims: To guide clinicians in selecting treatment options for esophageal squamous cell carcinoma (ESCC) patients,
reliable markers predictive of clinical outcome are desirable. This study analyzed the correlation of cyclophilin A
(CypA) and matrix metalloproteinase 9 (MMP9) in ESCC and their relationships to clinicopathological features
and survival.
Methods: We immunohistochemically investigated 70 specimens of ESCC tissues using CypA and MMP9
antibodies. Then, the correlations between CypA and MMP9 expression and clinicopathological features and its
prognostic relevance were determined.
Results: Significant correlations were only found in high level of CypA and MMP9 expression with tumor
differentiation and lymph node status. Significant positive correlations were found between the expression status
of CypA and that of MMP9. Overexpression of CypA and metastasis were significantly associated with shorter
progression free survival times in univariate analysis. Multivariate analysis confirmed that CypA expression was an
independent prognostic factor.
Conclusions: CypA might be correlated with the differentiation, and its elevated expression may be an adverse
prognostic indicator for the patients of ESCC. CypA/MMP9 signal pathway may be attributed to the malignant
transformation of ESCC, and attention should be paid to a possible target for therapy.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1166551968105508.
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Esophageal squamous cell carcinoma (ESCC) is a highly
aggressive neoplasm with geographic characters and poor
prognosis. About one-half of all ESCC cases in the world
occur in China [1]. Despite a myriad of improvements in
both diagnostic and therapeutic techniques over the past
three decades, ESCC continues to have a poor prognosis,
with 5-year survival rates between 10-13% [2]. Research
over the last 30 years has identified a number of genetic
alterations relating to induction of ESCC. Besides, some of* Correspondence: liyi_0712@163.com
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reproduction in any medium, provided the orthem were shown to be of prognostic significance. However,
further comprehensive investigations and new clues were
expected. To guide clinicians in selecting treatment op-
tions for ESCC patients, reliable markers predictive of
poor clinical outcome are desirable.
Cyclophilin A (CypA) was originally identified as the
intracellular receptor for cyclosporin A (CsA) [3]. It is
implicated in several diseases, including viral infection,
cardiovascular disease, inflammatory diseases, and cancer
[4-7]. The role of CypA in cancer has recently drawn
attention. Various cancers, including ESCC over-expressed
CypA [8-13]. Although much effort has been devoted to
the function of CypA in cancer, but few research has been
undertaken to evaluate the clinical value of CypA in ESCC.
Matrix metalloproteinases (MMPs) are a highly regulatedhis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.








<65 48 13 35
≥65 22 3 19
Gender 0.555
Male 45 9 36
Female 25 7 18
Smoking 0.343
Yes (>40 pack-years) 51 10 41
No 19 6 13
Drink 0.580
Yes (>50 ml/day) 39 10 29
No 31 6 25
Differentiation <0.01
Well + Moderate 39 16 23
Poor 31 0 31
TNM stage 0.123
I–II 22 8 14
III–IV 48 8 40
Lymph node status 0.010
Metastasis 38 4 34
No metastasis 32 12 20
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associated with the development and progression of
tumors [14]. MMP9, a target gene of CypA, was revealed
over-expression in ESCC [15].
In this study, we investigated whether expression levels
of CypA and MMP9 have prognostic significance in ESCC.
Immunohistochemical expression of CypA and MMP9
were examined in a total of 70 ESCC patients who under-
went a surgical resection without any neoadjuvant treat-
ment. We also investigated whether the expression levels
of CypA correlate with that of MMP9 in this patient
population and their prognostic value.
Materials and methods
Patients
ESCC patients who were confirmed by pathology were
collected in the First Affiliated Hospital of Xi’an Jiaotong
University from 2004 to 2009, and also received surgical
treatment. After following-up visits, 70 patients who
had complete clinical data were selected. None of these
70 patients received neoadjuvant therapy before operation.
Patients were followed closely until December 31, 2012,
and the range of the follow-up period was 1 to 25 months
(median, 9.33 months). Computed tomography (CT)
was performed at least every 6 months to detect recurrence.
Differentiation grade, TNM stage and lymph node status
were conducted according to UICC/AJCC TNM classifi-
cation (seventh edition). The clinicopathological features
of patients are shown in Table 1. The Institutional Ethics
Committee approval for this project was obtained from
Institutional Review Board of First Affiliated Hospital of
Xi’an Jiaotong University.
Immunohistochemical staining
Tissue specimens were fixed in neutral buffered formalin
(10% v/v formalin in water; pH 7.4) and embedded in
paraffin wax. Serial sections of 4-μm thickness were
cut and mounted on charged glass slides. The mono-
clonal antibody against CypA (1:400; Abcam, Cambridge,
UK) and MMP9 (1:800; Santa Cruz Biotechnology, CA,
USA) were used respectively. The Streptavidin-Peroxidase
technique (Golden Bridge International: SP-9000) was
used. An irrelevant rabbit antiserum served as a nega-
tive control. Sections were counterstained with Mayer’s
hematoxylin.
Immunohistochemical analysis
Two pathologists who were blinded to clinical evaluated
staining results independently and co-observed for a
consensus when they were divergent with the method
as described. Both of the percentage of positive cells
and the strength of the staining were considered in the
following method. 5 degree magnification visions were
chose randomly under the optical microscope, thecalculation of results as followed: the percentage of
positive cells in 0%-5% was counted 0; the percentage
of positive cells in 5%-25% was counted 1; 26%-50%
was counted 2; 51%-75% was counted 3; ≥ 76% was
counted 4. On the respect of staining strength, the
score for tumor cells without stain is 0; straw yellow
for 1; brown for 2; tan for 3. The staining index score
was the sum of the items above. For the purpose of
statistical analysis, the median of this series (25% of
malignant cells showing a stronger intensity than adjacent
non-tumor epithelium) was used as a cutoff value to
distinguish tumors with a low (<25) or high (≥25%) level
of CypA and MMP9 expression.Statistical analysis
Statistical analysis was done using the SPSS software
package (version 13.0, SPSS Institute). The association
between staining index and other categorical factors
potentially predictive of prognosis was analyzed using
the Fisher’s exact test. The Spearman’s rank correlation
coefficient was used for analyzing the association of
MMP9 expression levels with CypA expression status.
Progression-free survival (PFS) was defined as the time
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progression. Survival curve and median survival were
estimated by the Kaplan-Meier method. Their differences
were verified by log-rank test. Multivariate analysis
was done using the Cox proportional hazard regression
analysis. Results were considered statistically significant
if P < 0.05.
Results
Expression of CypA and MMP9 in ESCC and their
relationships to clinicopathological variables
Levels of CypA and MMP9 were evaluated by immuno-
histochemical analysis. CypA immunoreactivity showed
nuclear and cytoplasmic localization, while MMP9 was
found primarily in the cytosol. Figure 1 shows repre-
sentative expression patterns of CypA and MMP9 in
ESCC. Both high level of CypA and MMP9 expression
significantly correlated with the tumor differentiation
and metastasis. However, the high level rates were not
significantly correlated with gender, age, drink, smoking,
and TNM stage (Tables 1 and 2).
Association of CypA expression levels with MMP9
expression status
Since CypA is one of the important transcription factors
for MMP9 gene expression, we next investigated theFigure 1 Immunohistochemical expression of CypA and MMP9 in
immunohistological features with high levels of CypA expression in
staining shown nuclear and cytoplasmic localization; B, E Typical im
The MMP9 staining was present in the cytoplasm of tumor cells; C,
A-C × 200, D-F × 400.association of CypA expression levels with MMP9 expres-
sion status (Table 3). Of the 54 tumors containing a high
level of CypA immunoreactivity, a total of 50 cases dis-
played a high level of MMP9 expression. We calculated
the Spearman’s rank correlation coefficient to evaluate
the linear relationship. There was statistically signifi-
cant association of CypA expression status with MMP9
expression levels (r = 0.861,P < 0.01).
Survival analysis
Kaplan-Meier analysis was used to calculate the impact
of classic clinicopathologic features and protein expression
on PFS (Table 4, Figure 2). CypA, MMP9, differentiation,
and metastasis were associated with decreased survival
(P < 0.05), whereas other clinicopathological variables
were not significant. Cox regression analysis revealed a
statistically significant correlation between metastasis
and CypA expression and PFS (P < 0.01, Table 5).
Discussion
CypA, an 18-kDa cytosolic protein that is ubiquitously
expressed in prokaryotes and eukaryotes, is an important
component in protein folding. CypA has an activity
of peptidylprolyl cis-trans isomerase, which may play
important roles in protein folding, trafficking, assembly,
immune-modulator and cell signaling. It displays anesophageal squamous cell carcinoma. A, D Typical
esophageal squamous cell carcinoma (ESCC). The CypA
munohistological features with high levels of MMP9 in ESCC.
F Negative staining in ESCC. Magnifications:








<65 48 14 34
≥65 22 6 16
Gender 0.783
Male 45 12 33
Female 25 8 17
Smoking 0.146 0.301
Yes (>40 pack-years) 51 12 39
No 19 8 11
Drink 0.427
Yes (>50 ml/day) 39 13 26
No 31 7 24
Differentiation 0.003
Well + Moderate 39 17 22
Poor 31 3 28
TNM stage 0.397
I–II 22 8 12
III–IV 48 14 36
Lymph node status 0.016
Metastasis 38 6 32
No metastasis 32 14 18




free survival (months) P
Median ± SE 95% CI
CypA <0.01
Low 16 16.42 ± 1.16 17.08-21.76
High 54 7.42 ± 0.60 6.24-8.59
MMP9 <0.01
Low 20 16.332 ± 1.75 10.91-14.93
High 50 7.70 ± 0.62 6.49-8.91
Age 0.220
<65 48 11.47 ± 1.22 9.08-13.87
≥65 22 9.44 ± 1.23 7.03-11.84
Gender 0.950
Male 45 10.82 ± 1.24 8.38-13.25
Female 25 11.30 ± 1.45 8.46-14.15
Smoking 0.269
Yes (>40 pack-years) 51 10.06 ± 1.02 8.01-12.05
No 19 12.35 ± 1.82 8.79-15.92
Drink 0.406
Yes (>50 ml/day) 39 11.28 ± 1.25 8.83-13.72
No 31 10.07 ± 11.32 7.48-12.66
Differentiation <0.01
Well + Moderate 39 13.33 ± 1.28 10.82-15.84
Poor 31 7.07 ± 0.78 5.54-8.60
TNM stage 0.295
I–II 22 12.02 ± 1.87 8.36-15.67
III–IV 48 10.20 ± 1.02 8.20-12.19
Lymph node 0.041
Metastasis 38 8.79 ± 1.20 6.44-11.14
No metastasis 32 12.75 ± 1.20 10.40-15.10
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relates with poor outcome of the patients. Overexpression
of CypA was first demonstrated in hepatocellular carcin-
oma in 1998 [16], then a growing number of reports focus
on the role of CypA in cancer. Different types of cancers,
including lung cancer, colorectal cancer, pancreatic cancer,
breast cancer, squamous cell carcinoma, and melanoma
exhibit upregulated CypA [8-13]. Some researchers
have investigated the function of CypA during tumor
progression, including the stimulation of proliferation,
blockade of apoptosis, regulation of metastasis, malignant
transformation and drug resistant [17]. In the study of Qi
et al. [12], CypA was differentially expressed between
esophageal cancer cell lines and immortal cell line, whichTable 3 Association of MMP9 expression levels with CypA
expression status
Variables Total MMP9 P r
Low High
CypA <0.01 0.861
Low 16 16 0
High 54 4 50suggested that CypA may implicated in the esophageal
malignant transformation processes. Even so, the expression
and significance of CypA in ESCC remains incompletely
understood.
Metastasis is the primary cause of morbidity and
mortality in cancer patients. Stable CypA RNA-interfered
breast cancer and osteosarcoma cells showed reduced
migratory capacity [18]. MMPs were also associated
with tumor invasion and migration [19]. MMP9 plays a
pivotal role in the degradation of ECM [20]. In a micro-
array results, MMP9 were found regulated by CypA. RNA
interference assay also demonstrates that MMP9 were
regulated by CypA in SKHep1 cells [21]. The same result
was found by Qian et al. in non-small cell lung cancer
[22]. Further more, increased expression of MMP9 was
found in ESCC [15].
Figure 2 Kaplan-Meier survival analysis. Cumulative progression free survival differences between patients with high and low levels of protein
expression. P value was obtained using the log-rank test of the difference. A CypA; B MMP9.
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highly expressed in ESCC. Both high level of CypA
and MMP9 expression significantly correlated with the
tumor differentiation and metastasis. So, we may con-
clude that both CypA and MMP9 have an important
role in the progression of ESCC. Next, significant
positive correlations (Spearmen rank correlation) were
found between the expression status of CypA and that
of MMP9. This means MMP9 may be one of CypA
related interacting partners, suggesting that CypA may
regulate the expression of MMP9 . However, the exact
molecular mechanisms remain to be clarified. Overall,
the available data so far suggest that CypA pathwayTable 5 Multivariate Cox proportional hazards analysis





Low vs High 26.22 4.46-154.02 <0.01
MMP9
Low vs High 2.945 0.94-9.24 0.064
Lymph node
No metastasis vs Metastasis 0.587 0.271-1.274 0.178
TNM stage
I–II vs III–IV 0.657 0.319-1.353 0.255
Differentiation
Poor vs Well + Moderate 1.939 0.819-4.59 0.132may well be related to the genetic changes implicated
in ESCC progression.
There are lots of reports about different risk factors in
ESCC, including NDRG2, HSPA2, HAX-1, USP9X, and
so on [23-27]. The prognostic value of MMP-9 in cancer
was also investigated, but there were few reports about
that of CypA [28-31]. Although it was found no prognos-
tic significance of CypA in non-small cell lung cancer, but
overexpression of CypA was associated with decreased
survival in various cancers, including endometrial car-
cinoma, tongue squamous cell carcinoma, and renal
cell carcinoma. However, the prognosis value of CypA
in ESCC remains unknown. According to our results,
MMP-9 failed to predict patients’ prognosis, whereas
CypA was shown to be an independent prognostic
indicator in patients with ESCC. Take all these results
into consideration, CypA might be available not only
as clinical predictors, but also as targets for ESCC
treatment. We will focus on both the prognostic and
treatment value of CypA in furture.
The current study suggested that the high expression of
CypA proteins was associated with important clinicopatho-
logical parameters in ESCC. There was a significant positive
correlation between the expression status of CypA and
that of MMP9. Further, CypA was an important prog-
nostic indicator in cases of ESCC. Therefore, CypA/MMP9
signal pathway may be attributed to the malignant trans-
formation of ESCC, and attention should be paid to a
possible target for therapy.Competing interests
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